Table 1 |
|||||
|
Baseline demographics of participating patients |
|||||
| Characteristic |
ACZ885 |
||||
|
|
|||||
| 0.3 mg/kg (n = 6) |
1.0 mg/kg (n = 6) |
3.0 mg/kg (n = 6) |
mg/kg (n = 20) |
Placebo (n = 15) |
|
|
|
|||||
| Age (years; mean ± SD) |
61 ± 7 |
53 ± 14 |
57 ± 7 |
50 ± 11 |
55 ± 10 |
| hsCRP (mg/l; median [range]) |
17.8 (1.6–95.3) |
43.8 (5.8–89.3) |
3.0 (2.0–43.4) |
11.1 (1.5–28.4) |
6.4 (0.2–66.2) |
| DAS28 (mean ± SD) |
6.5 ± 0.8 |
6.6 ± 1.2 |
6.7 ± 1.5 |
6.2 ± 0.7 |
6.7 ± 0.6 |
| Number of tender joints (mean ± SD) |
17 ± 9.2 |
15 ± 6.2 |
22 ± 8.5 |
17 ± 7.3 |
20 ± 6.3 |
| Number of swollen joints (mean ± SD) |
13 ± 6.3 |
12 ± 4.3 |
12 ± 7.4 |
11 ± 4.8 |
12 ± 5.2 |
| Methotrexate dose (n/mg median [range])a |
|||||
| Oral |
6/17.5 (15–25) |
5/15 (10–15) |
4/15 (15–15) |
13/15 (10–22.5) |
5/15 (10–20) |
| Parenteral |
0 |
1/10 (10–10) |
2/22.5 (20–25) |
7/15 (10–22.5) |
10/15 (10–25) |
|
|
|||||
|
aNumbers of patients receiving 15 mg/week were 2, 4, 4, 10 and 6 in the 0.3, 1, 3, 10 mg/kg and placebo cohorts, respectively. SD, standard deviation. |
|||||
|
Alten et al. Arthritis Research & Therapy 2008 10:R67 doi:10.1186/ar2438 |
|||||
